Mesoblast's Stem Cell Therapy Works in Phase II HF Trial

LONDON – Mesoblast Ltd. has revived hopes for the potential use of stem cells to treat heart disease, delivering positive results in a 60-patient Phase II trial of Revascor in congestive heart failure, and significantly for the allogeneic cell therapy, reporting the product did not provoke any adverse immune responses.